Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Must Watch Stocks: Ariad Pharmaceuticals, Hewlett-Packard Company, Camtek Ltd, Buka Ventures Inc

CAMT, HPQ, NNRX

New York, November 26, 2013 /Accesswire/ - Market Buzz Report, a leading penny stock newsletters provider, issues major news alert for Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Hewlett-Packard Company (NYSE:HPQ), Camtek LTD. (NASDAQ:CAMT), Buka Ventures Inc (OTCBB:NNRX)

Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) is trading higher by 10% in premarket action after soaring 100% in past one week. The shares are looking build on Friday's big rally, which was sparked by a bit of much needed good news for Iclusig courtesy of the CHMP. Market chatter suggests BMO has upped their price target on the shares to $4 from $2.50.

Free Urgent Insider Catalyst Report For ARIA Available Here: http://marketbuzzreport.com/index.php?code=ARIA (Or Copy and paste the URL into your browser)

Last week, The CHMP renders a positive opinion on the continued availability of Ariad's (ARIA) Iclusig for "authorized indications" (various phases of dasatinib or nilotinib-resistant CML, dasatinib-resistant Ph+ ALL, etc.)The EMA has also made a few recommendations regarding how to cut down on the risk of occlusive vascular events. Suggestions include: The drug should not be used by patients with a history of heart attack or stroke, patients' cardiovascular status should be assessed prior to treatment, hypertension should be controlled over the course of Iclusig treatment, and monitoring should be in place to detect vascular occlusion or thromboembolism.

Hewlett-Packard Company (NYSE:HPQ) FQ4 results are due out after the bell, with analysts expecting that EPS dropped to $1 from $1.16 last year and that revenue slid 6.8% to $27.91B.SA author Trefis notes that while

H-P has launched new products and services "to reinvigorate its business lines," the company is "still plagued by a weak enterprise demand and a slowing PC market."Joe Panettieri is looking for CEO Meg Whitman to address five "key areas," including channel partners, networking, 3-D printing and the cloud.

Free Urgent Insider Catalyst Report For HPQ Available Here: http://marketbuzzreport.com/index.php?code=HPQ (Or Copy and paste the URL into your browser)

Camtek LTD.(NASDAQ:CAMT) surges 25% pre-market on heavy volume, adding to 140% in past two trading session. The most probable cause of the move? A bull argument by SA contributor super-trades which claims that the stock should be considered a 3D printing play given the company's planned 2014 roll out of a commercial 3D printer that manufactures Printed Circuit Boards. The author calls it "the world's first."

Free Urgent Insider Catalyst Report For CAMT Available Here: http://marketbuzzreport.com/index.php?code=CAMT (Or Copy and paste the URL into your browser)

Buka Ventures Inc(OTCBB:NNRX) announced that the Company has completed a Licence Agreement with Genesar Nutraceuticals, LLC to acquire the worldwide exclusive marketing and distributing rights to GenEpic™, a natural therapeutic treatment formula currently the subject of an IRB reviewed (FDA regulated) phase II human clinical study on prostate cancer treatment and recovery.

Free Urgent Insider Catalyst Report For NNRX Available Here: http://marketbuzzreport.com/index.php?code=NNRX (Or Copy and paste the URL into your browser)

Under the terms of the Licence Agreement, Nutranomics will hold the worldwide licence for GenEpic™ including all intellectual property relating to it and any associated trade secrets for a period of thirty (30) years in exchange for the following: i) 100,000 restricted shares of NNRX common stock; ii) a royalty fee of $4.00/box of GenEpic™ sold by Nutranomics; and iii) payment of $200,000 as advance royalties on the first 4,000 boxes sold, due in December 2013.

USMarketBuzz.com is an investment community that Focuses on MicroCap Securities. USMarketBuzz.com is an authorative authentic Google News Site and Leading Provider of Investment Awareness and Featured Company Profiles. If you would like more information regarding our news coverage solutions, please visit http://www.USMarketBuzz.com/ for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.USMarketBuzz.com/.

Follow us on Facebook: https://www.facebook.com/usmarket.buzz

Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PREPROMO to 27126. (SMS alerts are free, however data rates may apply, check your wireless plan for details.)



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today